Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT06047262
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT06047262
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Belgium, France, Germany, Switzerland
- Registry status
- Recruiting
Technical summary
Registry record NCT06047262. Randomized; double masking; primary purpose treatment. Start 2024-07-09 (actual); primary completion 2028-07-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia
- Acronym
- Dapan-Dia
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Dapansutrile
- Intervention (Drug)
- Placebo
- Lead sponsor
- Marc Donath
- Collaborator
- European Union
- Collaborator
- State Secretariat for Education Research and Innovation, Switzerland
- Collaborator
- Olatec Therapeutics, Inc.
- Collaborator
- Departement Klinische Forschung Universität Basel
- Collaborator
- CTU Kantonsspital Baden
Record details
- Record id
cardio:ct-nct06047262- Content hash
b32a3046cb5c6ddcd60c185364708ac77da16fb51bf4cd2b75be5f521550134f